Form 4: Amneal Pharmaceuticals Director Receives Restricted Stock Units

Deborah M. Autor, a director at Amneal Pharmaceuticals, was granted 40,258 restricted stock units on May 2, 2024.

Summary

• Deborah M. Autor, a director of Amneal Pharmaceuticals, Inc. (AMRX), received 40,258 restricted stock units on May 2, 2024.
• These restricted stock units represent a contingent right to receive one share of the Issuer's Class A Common Stock each.
• The restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
• Following the transaction, Ms. Autor directly owns 40,258 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning director interests with shareholder value.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders, incentivizing her to work towards the company's success.

Future Outlook

The restricted stock units will vest based on the terms described in the document, potentially leading to the issuance of Class A Common Stock.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the grant of restricted stock units positively as it incentivizes the director to work towards increasing shareholder value.

Key Dates